{"id":"pemcarbo","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while carboplatin forms DNA cross-links that prevent replication and transcription. Together, these agents provide synergistic cytotoxic activity against rapidly dividing cancer cells. This combination is commonly used in lung cancer and mesothelioma treatment.","oneSentence":"PemCarbo is a combination chemotherapy regimen pairing pemetrexed (an antifolate antimetabolite) with carboplatin (a platinum-based alkylating agent) to inhibit DNA synthesis and repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:32.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (likely first-line or maintenance)"},{"name":"Malignant pleural mesothelioma (possible indication)"}]},"trialDetails":[{"nctId":"NCT01593293","phase":"PHASE3","title":"Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-03","conditions":"Non-small Cell Lung Cancer","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alimta: brand name of Pemetrexed"],"phase":"phase_3","status":"active","brandName":"PemCarbo","genericName":"PemCarbo","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PemCarbo is a combination chemotherapy regimen pairing pemetrexed (an antifolate antimetabolite) with carboplatin (a platinum-based alkylating agent) to inhibit DNA synthesis and repair. Used for Non-small cell lung cancer (likely first-line or maintenance), Malignant pleural mesothelioma (possible indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}